Zevra Therapeutics (ZVRA) Amortization - Intangibles (2023 - 2026)

Zevra Therapeutics has reported Amortization - Intangibles for 4 years, with the latest figure at $316000.0 in Q1 2026.

• For the quarter ending Q1 2026, Amortization - Intangibles fell 80.43% year-over-year to $316000.0; the trailing twelve-month figure through Mar 2026 stood at $2.6 million (down 59.46% YoY), and the FY2025 full-year result was $3.9 million, down 38.06% from the prior year.
• Amortization - Intangibles for Q1 2026 stood at $316000.0, roughly flat from $316000.0 in the prior quarter.
• The five-year high for Amortization - Intangibles was $1.6 million in Q4 2024, with the low at $315000.0 in Q3 2025.
• Historically, Amortization - Intangibles has averaged $1.1 million across 4 years, with a median of $1.5 million in 2024.
• Annual changes were most pronounced in 2024 — Amortization - Intangibles soared 109.33% — and 2025, when it plunged 80.45%.
• Zevra Therapeutics' Amortization - Intangibles stood at $772000.0 in 2023, then jumped by 109.33% to $1.6 million in 2024, then sank by 80.45% to $316000.0 in 2025, then changed by 0.0% to $316000.0 in 2026.
• The last three Amortization - Intangibles figures came in at $316000.0 (Q1 2026), $316000.0 (Q4 2025), and $315000.0 (Q3 2025), per Business Quant data.